<DOC>
	<DOCNO>NCT01225731</DOCNO>
	<brief_summary>This response-driven study tildrakuzumab treatment moderate severe chronic plaque psoriasis . The primary study hypothesis one dose tildrakizumab superior placebo treatment psoriasis .</brief_summary>
	<brief_title>A Study Determine Optimal Dose Tildrakizumab ( SCH 900222/MK-3222 ) Treatment Moderate-to-severe Chronic Plaque Psoriasis ( P05495 ) ( MK-3222-003 )</brief_title>
	<detailed_description>Each participant enrol trial approximately 72-76 week . Each participant receive assign treatment Weeks 0 4 Part I . At Week 16 , dosage treatment patient assign may adjust base Psoriasis Area Severity Index ( PASI ) 75 response ( responder v non-responder ) . Participants receive study medication every 12 week Part 2 ( Weeks 16 52 ) ; participant receive placebo Part 2 . Part 3 observational period subject continue monitor monthly basis Week 72 . Subjects receive study medication Part 3 .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Adult participant ( ≥18 year age ) diagnosis moderatetosevere chronic plaque psoriasis ( define ≥10 % body surface area [ BSA ] involvement , `` moderate '' great score Physician 's Global Assessment [ PGA ] scale , PASI score ≥12 Baseline ) Participants must diagnosis predominantly plaque psoriasis ≥6 month ( determine interview confirmation diagnosis physical examination investigator ) consider candidate phototherapy systemic therapy . Participants psoriatic arthritis may include study Nonplaque form psoriasis specifically erythrodermic psoriasis , predominantly pustular psoriasis , medicationinduced medicationexacerbated psoriasis , new onset guttate psoriasis Participants require oral injectable corticosteroid trial Presence infection require treatment systemic antibiotic within 2 week prior Screening , serious infection ( eg , pneumonia , cellulitis , bone joint infection ) require hospitalization treatment intravenous antibiotic within 8 week prior Screening Participants evidence active untreated latent tuberculosis ( TB ) accord Screening criterion specify protocol . ( Prophylactic treatment latent TB per local guideline must initiate least 4 week prior treatment study medication ) Previous exposure agent target interleukin12 ( IL12 ) and/or Interleukin23 ( IL23 ) Participants prior exposure two tumor necrosis factor ( TNF ) antagonists discontinuation due lack efficacy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>